Issue Date: December 19, 2011
Selcia Doubles Its Radiolabeling Labs
Selcia has doubled its capacity to conduct carbon-14 radiolabeling projects in Ongar, Essex, England. The company says it has been preparing radiolabeled active pharmaceutical ingredients for customers with compounds in Phase I clinical trials since September 2010, after certification by British authorities. Drug companies create radiolabeled versions of developmental compounds for metabolism, mass-balance, and microtracer studies, Selcia notes.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society